Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

and non-small cell lung cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BCRP (2) Tim3 (3) VISTA (1) 11β-HSD (2) 17β-HSD (2) ACSL Family (3) ADAMTS (1) ADC Antibody (9) ADC Payload (4) Adenosine Receptor (2) Akt (77) Aldehyde Dehydrogenase (ALDH) (1) Aldose Reductase (1) Aminotransferases (Transaminases) (1) AMPK (7) Amylases (2) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (29) Antibiotic (3) Antibody-Drug Conjugates (ADCs) (13) Antifolate (2) Apoptosis (206) ASK1 (1) Atg8/LC3 (1) ATM/ATR (2) ATP Synthase (1) ATTECs (1) Aurora Kinase (2) AUTACs (1) Autophagy (44) Bacterial (7) Bcl-2 Family (26) Bcr-Abl (1) Beclin1 (3) Biochemical Assay Reagents (4) BMX Kinase (1) Bradykinin Receptor (1) Btk (1) c-Fms (1) c-Met/HGFR (28) c-Myc (4) C-type Lectin-like Receptors (CTLRs) (1) Cadherin (2) Calcium Channel (1) CaMK (2) Cannabinoid Receptor (2) Carbamoyl Phosphate Synthetase (CPS) (1) Carbonic Anhydrase (1) Caspase (33) CCR (2) CD276/B7-H3 (4) CD28 (2) CD3 (1) CD73 (1) CDK (24) Checkpoint Kinase (Chk) (1) Chloride Channel (2) CMV (1) Complement System (1) COX (7) CTLA-4 (4) CXCR (1) Cyclin G-associated Kinase (GAK) (2) Cytochrome P450 (4) Dihydrofolate reductase (DHFR) (1) Dihydropyrimidine Dehydrogenase (DPD) (1) Dipeptidyl Peptidase (1) Discoidin Domain Receptor (4) DNA Alkylator/Crosslinker (2) DNA Methyltransferase (3) DNA-PK (3) DNA/RNA Synthesis (24) Drug Derivative (19) Drug Intermediate (3) Drug Metabolite (10) Drug-Linker Conjugates for ADC (6) E-Selectin (4) E1/E2/E3 Enzyme (3) EGFR (154) Elastase (1) Endogenous Metabolite (12) Ephrin Receptor (1) Epigenetic Reader Domain (12) ERK (52) Estrogen Receptor/ERR (2) Eukaryotic Initiation Factor (eIF) (1) FAK (5) FAP (2) Fc Receptor (FcR) (1) Ferroptosis (19) FGFR (2) FLT3 (2) Fluorescent Dye (1) Folate Receptor (FR) (1) Fungal (6) G-quadruplex (2) GABA Receptor (1) GLP Receptor (1) Glucosylceramide Synthase (GCS) (1) GLUT (1) Glutaminase (2) Glutathione Peroxidase (5) Glycosidase (3) GSK-3 (3) HDAC (7) Hexokinase (2) HIF/HIF Prolyl-Hydroxylase (3) Hippo (MST) (1) Histone Demethylase (2) Histone Methyltransferase (10) HIV (2) hnRNP (1) HSP (12) HSV (2) HyT (3) IAP (3) IFNAR (3) IGF-1R (1) IKK (3) Indoleamine 2,3-Dioxygenase (IDO) (2) Insecticide (1) Insulin Receptor (2) Integrin (2) Interleukin Related (10) IRE1 (3) Isotope-Labeled Compounds (16) JAK (4) JNK (9) Keap1-Nrf2 (10) Lactate Dehydrogenase (2) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (3) Liposome (1) Lipoxygenase (1) Macrophage migration inhibitory factor (MIF) (2) MAP3K (1) MAP4K (1) MAPKAPK2 (MK2) (1) MCHR1 (GPR24) (1) MDM-2/p53 (12) MEK (14) Mesothelin (1) Methionine Adenosyltransferase (MAT) (2) METTL3 (2) mGluR (1) MHC (1) Microtubule/Tubulin (22) Mitochondrial Metabolism (5) Mitophagy (3) MMP (17) MNK (1) Molecular Glues (5) Monoamine Oxidase (1) mTOR (20) Na+/H+ Exchanger (NHE) (1) NF-κB (15) NO Synthase (4) Nucleoside Antimetabolite/Analog (6) Opioid Receptor (3) Oxidative Phosphorylation (1) P-glycoprotein (6) P2X Receptor (1) p38 MAPK (30) p62 (2) PAK (1) Paraptosis (1) PARP (12) PD-1/PD-L1 (25) PDGFR (2) PEPCK (1) Peptide-Drug Conjugates (PDCs) (1) PERK (5) Phosphatase (5) Phosphodiesterase (PDE) (2) Phospholipase (1) PhosTACs (2) PI3K (33) PI5P4K (1) PINK1/Parkin (3) PKC (4) Polo-like Kinase (PLK) (5) Potassium Channel (2) PPAR (2) Pregnane X Receptor (PXR) (1) Prostaglandin Receptor (2) PROTACs (40) Proteasome (2) Proton Pump (1) PTEN (2) Pyroptosis (3) Pyruvate Kinase (1) RAD51 (2) Raf (7) Ras (48) Reactive Oxygen Species (ROS) (31) Reference Standards (31) RET (5) Ribosomal S6 Kinase (RSK) (2) RIP kinase (1) ROCK (2) ROR (2) ROS Kinase (6) SARS-CoV (4) SF3B1 (1) Sigma Receptor (2) Small Interfering RNA (siRNA) (1) Sodium Phosphate Cotransporter (1) SOS1 (1) Src (3) STAT (21) Stearoyl-CoA Desaturase (SCD) (2) STING (4) Survivin (7) SWI/SNF Complex (6) Syk (1) TAM Receptor (9) Target Protein Ligand-Linker Conjugates (1) Tau Protein (1) TGF-beta/Smad (5) TGF-β Receptor (1) Tie (2) TNF Receptor (9) Toll-like Receptor (TLR) (4) Topoisomerase (13) Transmembrane Glycoprotein (9) Trk Receptor (3) TROP2 (3) TRP Channel (5) TrxR (4) Tyrosinase (1) ULK (4) VDAC (1) VEGFR (26) Wee1 (4) Wnt (6) YAP (4) β-catenin (6) γ-secretase (1)
By Research Areas:	Cancer (701) Cardiovascular Disease (10) Endocrinology (5) Infection (33) Inflammation/Immunology (81) Metabolic Disease (18) Neurological Disease (33)
Click Chemistry:	PROTAC Synthesis (2) Alkynes (7)
Oligonucleotides:	Fluorescent Lipids (1) Pegylated Lipids (1) Nucleoside Analogs (1) CpG ODNs (1) Antisense Oligonucleotides (5) Cytidine (1)

712

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: BCRP Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0162

Luteolin Maximum Cited Publications 89 Publications Verification Luteoline; Luteolol; Digitoflavone	Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells .

HY-P9903

Nivolumab Maximum Cited Publications 23 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Infection Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-112288

C188-9 30+ Cited Publications TTI-101	STAT Apoptosis DNA Methyltransferase	Metabolic Disease Inflammation/Immunology Cancer
C188-9 (TTI-101) is a STAT3 inhibitor with a K_d value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia .

HY-110171

iMDK 5 Publications Verification	PI3K	Cancer
iMDK is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice .

HY-156002

LUNA18 Paluratide	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

HY-P99269

Sibrotuzumab 1 Publications Verification BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-P990957

Ficerafusp alfa BCA-101; FMAB2	EGFR TGF-beta/Smad	Inflammation/Immunology Cancer
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a K_d of 2.58 nM against EGFR and a K_d of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .

HY-145729

Danvatirsen AZD9150	STAT Apoptosis	Cancer
Danvatirsen (AZD9150) is an antisense oligonucleotide targeting STAT3. Danvatirsen reduces the viability and promotes apoptosis of leukemia cell lines. Danvatirsen inhibits the expression of endogenous STAT3 and its downstream target genes, and reduces the proliferation and tumorigenicity of neuroblastoma and lymphoma cells. Danvatirsen inhibited tumor growth in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen achieves STAT3 mRNA and protein depletion in a mouse model of epidermoid carcinoma. Danvatirsen can be used in research related to lymphoma, myelodysplastic syndrome, acute myeloid leukemia, neuroblastoma and non-small cell lung cancer .

HY-14907

Verubulin MPC 6827	Microtubule/Tubulin	Cancer
Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research .

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant Antibody	Integrin Apoptosis	Cancer
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a K_d value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .

HY-P99202

Vibostolimab	Transmembrane Glycoprotein	Cancer
Vibostolimab is an anti-TIGIT (*T cell* immunoglobulin and ITIM domain*) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small* cell lung cancer (NSCLC) and melanoma research .

HY-P990042

Gotistobart ONC-392; BNT 316	CTLA-4	Inflammation/Immunology Cancer
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer .

HY-P99961

Tifcemalimab JS004; Icatolimab	CD28	Cancer
Tifcemalimab (JS004; Icatolimab) is a humanized IgG4 monoclonal antibody against BTLA (B and T lymphocyte attenuator). By binding to BTLA, tifcemalimab blocks the interaction of HVEM-BTLA, thereby inhibiting the BTLA-mediated inhibitory signaling pathway. Tifcemalimab can be used in research related to squamous cell non-small cell lung cancer .

HY-P990704

Rilvegostomig AZD-2936	PD-1/PD-L1 Transmembrane Glycoprotein	Cancer
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .

HY-118263

Dacomitinib hydrate 25+ Cited Publications PF-00299804 hydrate; PF-299804 hydrate	EGFR	Cancer
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .

HY-160715

BNT411	Toll-like Receptor (TLR)	Cancer
BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) .

HY-P99223

Tovetumab MEDI-575	PDGFR	Cancer
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .

HY-161828

JWZ-5-13	PROTACs CDK	Cancer
JWZ-5-13 is a CDK7 PROTAC degrader. JWZ-5-13 inhibits the proliferation of cancer cells. JWZ-5-13 is applicable to the research of ovarian cancer, diffuse large B-cell lymphoma, acute T-lymphoblastic leukemia and non-small cell lung cancer .

HY-113418

Beta-Cortol	Endogenous Metabolite	Cancer
Beta-Cortol is an O-glycosylated compound and cortisol metabolite. It can be isolated from the leaves of mulberry cultivar Yu 711, and its concentration decreases significantly when the plant is subjected to drought stress. Beta-Cortol serves as a biomarker, as serum Beta-Cortol levels in early non-small cell lung cancer models are downregulated to 1/8 of the preoperative level after tumor resection. Due to such dramatic changes under specific pathological conditions, Beta-Cortol is currently widely used in studies related to early non-small cell lung cancer .

HY-P99858

Domvanalimab AB154	Transmembrane Glycoprotein	Cancer
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .

HY-145729A

Danvatirsen sodium AZD9150 sodium	STAT Apoptosis	Cancer
Danvatirsen sodium (AZD9150 sodium) is an antisense oligonucleotide targeting STAT3. Danvatirsen sodium reduces the viability and promotes apoptosis of leukemia cell lines. Danvatirsen sodium inhibits the expression of endogenous STAT3 and its downstream target genes, and reduces the proliferation and tumorigenicity of neuroblastoma and lymphoma cells. Danvatirsen sodium inhibited tumor growth in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen sodium achieves STAT3 mRNA and protein depletion in a mouse model of epidermoid carcinoma. Danvatirsen sodium can be used in research related to lymphoma, myelodysplastic syndrome, acute myeloid leukemia, neuroblastoma and non-small cell lung cancer .

HY-168566

EV206	HSP	Cancer
EV206 is a Hsp70 binder and apoptosis inducer that binds to the N-terminal domain of Hsp70, promotes Hsp70 degradation via the ubiquitin-proteasome system, and reduces Hsp70 protein stability. EV206 induces apoptotic cell death, inhibits colony formation, and downregulates the expression of cancer stem cell-related markers in non-small cell lung cancer cells. EV206 inhibits the growth of H460 xenograft tumors in nude mice and can be used for the research of non-small cell lung cancer .

HY-148511

Vidutolimod CMP-001	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 Indoleamine 2,3-Dioxygenase (IDO)	Cancer
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .

HY-176774

L07-2	Toll-like Receptor (TLR) NF-κB	Cancer
L07-2 is a TLR7/8 agonist. L07-2 is a linker-toxin building block that can be used to synthesize immunostimulatory antibody conjugates (ISACs) for cancer research. L07-2 can be used to studies related to tumors such as non-small cell lung cancer .

HY-P991193

NGM-438	TNF Receptor	Cancer
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a K_a of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 ⁺ T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .

HY-148803

Vabametkib	c-Met/HGFR	Cancer
Vabametkib is a MET TKI inhibitor. Vabametkib can be used in research on non-small cell lung cancer (NSCLC) .

HY-124321

Metralindole hydrochloride	CDK	Cancer
Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .

HY-W303895

Luteolin monohydrate 85+ Cited Publications	Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite	Others Cancer
Luteolin (monohydrate) is the monohydrate of Luteolin. Luteolin (Luteoline), a flavonoid, is also a potent Nrf2 inhibitor. Luteolin has anti-inflammatory and anticancer properties, induces apoptosis and cell cycle arrest in multiple human cancer cell lines, including non-small lung cancer cells, and inhibits cell metastasis and angiogenesis .

HY-18030A

CEP-28122 mesylate salt	Anaplastic lymphoma kinase (ALK)	Cancer
CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC₅₀ value of 1.9 nM. CEP-28122 mesylate salt has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate salt can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .

HY-18030

CEP-28122	Anaplastic lymphoma kinase (ALK)	Cancer
CEP-28122, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC₅₀ value of 1.9 nM. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 has good pharmacodynamic and pharmacokinetic activity. CEP-28122 can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .

HY-19637

SW044248	Topoisomerase	Cancer
SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.

HY-110335

OXA-06 hydrochloride	ROCK	Cancer
OXA-06 hydrochloride is an ATP-competitive ROCK inhibitor that blocks anchorage-dependent growth and invasion of non-small cell lung cancer cell lines. OXA-06 hydrochloride inhibits cofilin phosphorylation but does not stimulate apoptosis .

HY-P991237

Nezutatug HMBD-001	EGFR	Cancer
Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .

HY-148053

Rezivertinib analogue 1	Drug Metabolite	Cancer
Rezivertinib analogue 1 is a process impurity of osimertinib mesylate. Rezivertinib analogue 1 can be used in the study of non-small cell lung cancer .

HY-172237

Sosimerasib	Ras	Cancer
Sosimerasib is an orally active KRAS ^G12C inhibitor. Sosimerasib can be used in research related to non-small cell lung cancer .

HY-149842

AKT-IN-18	Akt Apoptosis	Cancer
AKT-IN-18, an inhibitor of Akt, inhibits Akt with an IC₅₀ of 69.45 μΜ in A549 cells. AKT-IN-18 induces apoptosis and can be used in non-small cell lung cancer study .

HY-13554

Annamycin	Antibiotic	Cancer
Annamycin is an anthracycline antibiotic with antitumor activity. Annamycin interacts with topoisomerase II, induces double-strand DNA breaks, triggers cell death, and exerts cytotoxic effects. In mice, Annamycin inhibits the growth of advanced subcutaneous melanoma and subcutaneous squamous cell carcinoma, and prolongs the survival of mice with subcutaneous reticulosarcoma and in lung cancer lung metastasis models. Annamycin can be used in research related to melanoma, reticulum cell sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer .

HY-147802

EGFR-IN-59	EGFR Apoptosis	Cancer
EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC₅₀=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC₅₀s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer .

HY-169741

DDR1-IN-10	Discoidin Domain Receptor	Cancer
DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small cell lung cancer, and gastric carcinoma .

HY-N16565

Piperchabamide B	Others	Cancer
Piperchabamide B is an amide alkaloid. Piperchabamide B can be isolated from the fruits of Piper longum. Piperchabamide B exhibits anticancer activity against acute promyelocytic leukemia, non-small cell lung cancer, and breast cancer .

HY-P991635

PF-07329640	TNF Receptor	Cancer
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .

HY-119182

Mitonafide 2 Publications Verification NSC 300288	DNA/RNA Synthesis	Cancer
Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia .

HY-18030B

CEP-28122 mesylate hydrochloride	Anaplastic lymphoma kinase (ALK)	Others
CEP-28122 mesylate hydrochloride, a diaminopyrimidine derivative, is a potent, selective, and orally active ALK inhibitor with an IC₅₀ value of 1.9 nM. CEP-28122 mesylate hydrochloride has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate hydrochloride has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate hydrochloride can be used for the study of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells .

HY-173460

RAS-IN-3	Ras	Cancer
RAS-IN-3 (compound 22) is a potent Ras inhibitor. ROCK-IN-12 can be used in the study of Non-small cell lung cancer and colorectal cancer .

HY-153943

DNA-PK-IN-10	DNA-PK	Cancer
DNA-PK-IN-10 is a DNA-PK inhibitor. DNA-PK-IN-10 can be used for the research of breast cancer and non-small cell lung cancer .

HY-17667

HDAC-IN-95	HDAC	Cancer
HDAC-IN-95 (Compound 9) is a HDAC inhibitor. HDAC-IN-95 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-151571

ZG1077	Ras	Cancer
ZG1077 is a covalent KRAS G12C inhibitor. ZG1077 can be used in the research of non-small cell lung cancer (NSCLC) .

HY-119694

Rotenolone	Drug Metabolite Mitochondrial Metabolism Cytochrome P450	Cancer
Rotenolone is a metabolite of Rotenone (HY-B1756), inhibitor of Mitochondrial complex I, and antiproliferative agent, with an IC₅₀ of 137 nM against bovine complex I. Rotenolone undergoes biotransformation via multiple cytochrome P450 isoenzymes in rainbow trout liver microsomes. Rotenolone exhibits anticancer activity against ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer, and colon cancer. Rotenolone can be used in studies related to ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer, and colon cancer .

HY-169514

TrkA-IN-8	Trk Receptor	Cancer
TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a K_d value of 3.3 µM. RTKs-IN-1 exhibits concentration-dependent inhibition of cell proliferation in lung cancer cell lines. RTKs-IN-1 holds potential for research in non-small cell lung cancer .

HY-157043

Antibacterial agent 161 trifluoromethanesulfonate	Bacterial	Infection
Antibacterial agent 161 trifluoromethanesulfonate (Compound 6) has antibacterial activity. Antibacterial agent 161 trifluoromethanesulfonate has high antiproliferative effects against colon cancer and non-small cell lung cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0162

Luteolin Maximum Cited Publications 89 Publications Verification Luteoline; Luteolol; Digitoflavone	Classification of Application Fields Flavones Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms other families Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification	Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite
Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells .

HY-N0164

Matrine 15+ Cited Publications Matridin-15-one; Vegard; α-Matrine	Alkaloids Piperidine Alkaloids Classification of Application Fields Leguminosae Sophora flavescens Aiton Plants Inflammation/Immunology Disease Research Fields Biological Pesticide Research Source Classification Cancer Agricultural Research	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-N6871

Abietic acid 3 Publications Verification	Infection Colophony Classification of Application Fields Pinaceae Ketones, Aldehydes, Acids Metabolic Disease Plants Inflammation/Immunology Disease Research Fields	Bacterial IKK Ferroptosis
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .

HY-N1462

Atractyloside potassium salt 4 Publications Verification	Cardiovascular Disease Classification of Application Fields Terpenoids Pterocarpus soyauxii Taub. Diterpenoids Plants Compositae Disease Research Fields Source Classification	Chloride Channel Autophagy mTOR AMPK
Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity .

HY-N0816

Polyphyllin VI 5+ Cited Publications	other families Classification of Application Fields Plants Disease Research Fields Steroids Cancer Source Classification	Apoptosis Pyroptosis
Polyphyllin VI, an active saponin, possess anti-cancer activities. Polyphyllin VI induces G2/M cell cycle arrest and triggers apoptosis. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer .

HY-N0234

Bavachinin 5+ Cited Publications 7-O-Methylbavachin; Bavachinin A	Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields Source Classification	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-101984

N6,N6-Dimethyladenosine 4 Publications Verification	Microorganisms Marine natural products Source Classification	Nucleoside Antimetabolite/Analog Adenosine Receptor Akt SARS-CoV
N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines .

HY-N1988

Cucurbitacin IIa 1 Publications Verification Hemslecin A	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Disease Research Fields Source Classification Cancer	Survivin Apoptosis EGFR Caspase p38 MAPK Autophagy MEK Raf ERK STAT CaMK
Cucurbitacin IIa (Hemslecin A) is an orally active, blood-brain barrier-permeable EGFR inhibitor with an IC₅₀ of 1.455 nM against human EGFR. Cucurbitacin IIa induces caspase-3-dependent apoptosis, downregulates survivin expression, enhances autophagy levels, disrupts the actin cytoskeleton via actin aggregation, arrests the cell cycle at the G2/M phase, and exerts anti-inflammatory activity by inhibiting the EGFR-MAPK signaling pathway. Cucurbitacin IIa can be used in the research of inflammation-related diseases, depression, and cancers such as non-small cell lung cancer .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite DNA/RNA Synthesis Apoptosis
Gemcitabine triphosphate (dFdCTP) trisodium is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate trisodium cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate trisodium shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate trisodium partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate trisodium disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate trisodium can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N1073

Wighteone 1 Publications Verification 6-Isopentenylgenistein; Erythrinin B	Leguminosae Genista ephedroides DC. Plants Isoflavones Source Classification	Apoptosis EGFR HSP ERK Akt
Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFR ^L858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFR ^L858R/T790M mutation, and fungal infections .

HY-125847

Salvianolic acid F 1 Publications Verification	Stilbenes Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	Ras PI3K Akt Caspase Apoptosis Bcl-2 Family NF-κB MMP
Salvianolic acid F is a KRAS inhibitor, especially for KRAS G12D. Salvianolic acid F inhibits NF-kB, MMP-9, and NO simultaneously. Salvianolic acid F inhibits cancer cell growth, invasion, and migration and induces apoptosis via the EP300/PI3K/AKT pathway in vitro. Salvianolic acid F inhibits the growth of KRAS-dependent lung cancer cells via the PI3K/AKT signaling pathway in vivo. Salvianolic acid F can be used in the research of various cancers, including KRAS G12D-driven non-small cell lung cancer (NSCLC) and ovarian cancer .

HY-N3980

Guaiol 1 Publications Verification Champacol; Guaiac alcohol	Infection Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Distemonanthus benthamianus Baill. Plants Compositae Disease Research Fields Source Classification	Autophagy RAD51
Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC₅₀ of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions ^[4]

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-N0819

Raddeanin A 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .

HY-N0600

Ginsenoside F3	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Araliaceae Source Classification	Interleukin Related IFNAR NF-κB
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a K_d value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer .

HY-N0162R

Luteolin (Standard) Maximum Cited Publications 89 Publications Verification Luteoline(Standard); Luteolol(Standard); Digitoflavone (Standard)	Human Gut Microbiota Metabolites Flavonoids other families Classification of Application Fields Phenols Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Reference Standards Keap1-Nrf2 Apoptosis Autophagy Endogenous Metabolite
Luteolin (Standard) is the analytical standard of Luteolin. This product is intended for research and analytical applications. Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells .

HY-N3126

Orsellinic acid	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Phenols Polyphenols Endogenous metabolite Disease Research Fields Source Classification	Drug Derivative Fungal Apoptosis Caspase PARP
Orsellinic acid is a Benzoic acid (HY-N0216) derivative. Orsellinic acid can be isolated from Chaetomium globosum endophytic on Ephedra fasciculata (Mormon tea). Orsellinic acid blocks PAF-mediated Apoptosis, inhibits caspase-3/7 activation, and PARP cleavage. Orsellinic acid can be used in research of neurons and various tumors (non-small cell lung cancer, breast cancer, neuroblastoma, pancreatic cancer) .

HY-128393

Trilinolein 1 Publications Verification	Natural Products Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification	PI3K Akt E-Selectin Apoptosis MMP MEK ERK
Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

HY-N0429

Diosbulbin B 1 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Clematis terniflora DC. Diterpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis MDM-2/p53 Bcl-2 Family CDK
Diosbulbin B, a diterpene lactone, is an anticancer agent. Diosbulbin B is an orally active component of Dioscorea. bulbifera L. Diosbulbin B can inhibit cell proliferation, induce G0/G1 phase arrest and apoptosis. Diosbulbin B can induce autophagy and mitochondrial dysfunction. Diosbulbin B can induce liver injury. Diosbulbin B can be used for the research of cancer, such as non-small cell lung cancer (NSCLC) .

HY-N2993

Polyporenic acid C	Triterpenes Classification of Application Fields Terpenoids Polyporaceae Poria cocos Plants Disease Research Fields Source Classification Cancer	Apoptosis Caspase PARP Akt PTEN MDM-2/p53 JNK
Polyporenic acid C is a lanostane-type triterpenoid. Polyporenic acid C can be isolated from Poria cocos. Polyporenic acid C causes the cleavage of caspase-8 and caspase-3, as well as the cleavage of PARP. Polyporenic acid C reduces the phosphorylation level of Akt (Ser473), increases the phosphorylation of PTEN and p53 (Ser15), and activates JNK. Polyporenic acid C induces Apoptosis. Polyporenic acid C shows anticancer activity against non-small cell lung cancer .

HY-N1408

trans-Trimethoxyresveratrol trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene	other families Stilbenes Classification of Application Fields Plants Disease Research Fields Source Classification Cancer	VEGFR Reactive Oxygen Species (ROS) Caspase Apoptosis
Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through VEGFR2. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma) .

HY-17026A

Gemcitabine triphosphate dFdCTP	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite DNA/RNA Synthesis Apoptosis
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N1401

20(R)-Ginsenoside Rh2 2 Publications Verification	Panax ginseng C. A. Meyer Infection Triterpenes Human Gut Microbiota Metabolites Classification of Application Fields Terpenoids Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Araliaceae Source Classification	MMP Apoptosis HSV DNA/RNA Synthesis NO Synthase Prostaglandin Receptor Reactive Oxygen Species (ROS) Akt
20(R)-Ginsenoside Rh2 is an orally active protopanaxadiol-type saponin with multiple biological activities. 20(R)-Ginsenoside Rh2 exerts a significant inhibitory effect on non-small cell lung cancer and liver cancer by inducing cell cycle arrest and promoting apoptosis. 20(R)-Ginsenoside Rh2 exerts anti-γ-herpesvirus effects by inhibiting viral DNA replication. 20(R)-Ginsenoside Rh2 inhibits inflammatory mediators by reducing the levels of NO, PGE2, and ROS; it can delay skin photoaging by reducing ROS and inhibiting MMP-9/2 activity. 20(R)-Ginsenoside Rh2 accelerates the recovery after muscle injury by activating the Akt1/PKB signaling pathway. 20(R)-Ginsenoside Rh2 can inhibit osteoclast formation and exert an anti-osteoporosis effect .

HY-113418

Beta-Cortol	Structural Classification Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite
Beta-Cortol is an O-glycosylated compound and cortisol metabolite. It can be isolated from the leaves of mulberry cultivar Yu 711, and its concentration decreases significantly when the plant is subjected to drought stress. Beta-Cortol serves as a biomarker, as serum Beta-Cortol levels in early non-small cell lung cancer models are downregulated to 1/8 of the preoperative level after tumor resection. Due to such dramatic changes under specific pathological conditions, Beta-Cortol is currently widely used in studies related to early non-small cell lung cancer .

HY-N16129

Diplacone Nymphaeol A; Propolin C	Structural Classification Flavonoids Flavones Paulownia tomentosa (Thunb.) Steud. Scrophulariaceae Plants Source Classification	COX Reactive Oxygen Species (ROS) Calcium Channel Ferroptosis Mitochondrial Metabolism MMP
Diplacone is an orally active geranyl flavanone. It is isolated from the fruits of Paulownia tomentosa. Diplacone reduces COX-2 levels and increases the pro-MMP2/MMP2 ratio. It induces ferroptosis-mediated cell death. Diplacone enhances mitochondrial Ca ²⁺ influx and ROS production. It possesses anti-inflammatory and free radical-scavenging activities. Diplacone can be used in research related to ulcerative colitis and non-small cell lung cancer .

HY-N3000

6-Methoxydihydrosanguinarine	Alkaloids Structural Classification Classification of Application Fields Quinoline Alkaloids Macleaya cordata (Willd.) R. Br. Plants Disease Research Fields Papaveraceae Source Classification Cancer	JNK IRE1 Akt mTOR YAP Reactive Oxygen Species (ROS) Autophagy Apoptosis Ferroptosis Fungal
6-Methoxydihydrosanguinarine is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer .

HY-W018324

5-Hydroxymethylcytosine 5hmC	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) .

HY-121811

Pongamol Lanceolatin C	Structural Classification Pongamia pinnata (L.) Pierre Leguminosae Ketones, Aldehydes, Acids Derris trifoliata Lour. Plants Source Classification	Glycosidase Phosphatase Interleukin Related TNF Receptor COX Beclin1 GLUT FAK Akt mTOR p38 MAPK Keap1-Nrf2 Apoptosis Amyloid-β Tau Protein Autophagy
Pongamol (Lanceolatin C) is an orally active flavonoid with an IC₅₀ of 75 μM and a K_i of 58 μM against PTPase-1B, and an IC₅₀ of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol exhibits antibacterial activity. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .

HY-N1930

(-)-Hinesol Hinesol	Structural Classification Terpenoids Sesquiterpenes Plants Compositae Erythrina sigmoidea Hua	Apoptosis
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .

HY-N4309

Lotusine	Cardiovascular Disease Alkaloids Structural Classification other families Classification of Application Fields Phenols Polyphenols Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Amylases Glycosidase
Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against α-amylase and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-N7694

Isotoosendanin 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Melia toosendan Sieb. et Zucc. Plants Meliaceae Inflammation/Immunology Disease Research Fields Source Classification	TGF-β Receptor JAK STAT Apoptosis
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-N0867

13-Oxyingenol-13-dodecanoate	Structural Classification Classification of Application Fields Terpenoids Gramineae Other Diseases Diterpenoids Leptochloa chinensis (Linn.) Nees Plants Disease Research Fields Source Classification	HIV ULK Bcl-2 Family
13-Oxyingenol-dodecanoate (13OD) is a tumor suppressor agent. 13-Oxyingenol-dodecanoate has anti-HIV-1 activity with EC₅₀ value of 33.7 nM .13-Oxyingenol-dodecanoate can induce the expression of ULK1 to effect mitochondrial dysfunction and cellular autophagy. 13-Oxyingenol-dodecanoate also increases the expression of BAX and suppresses the expression of BCL-2 to effect apoptosis .

HY-101984R

N6,N6-Dimethyladenosine (Standard)	Microorganisms Source Classification	Reference Standards Nucleoside Antimetabolite/Analog Adenosine Receptor Akt SARS-CoV
N6,N6-Dimethyladenosine (Standard) is the analytical standard of N6,N6-Dimethyladenosine (HY-101984). This product is intended for research and analytical applications. N6,N6-Dimethyladenosine, a modified ribonucleoside, is an endogenous A3 adenosine receptor ligand. N6,N6-Dimethyladenosine is an AKT inhibitor with antitumor effects. N6, N6-Dimethyladenosine targets SARS-CoV-2 entry protein ADAM17. N6, N6-Dimethyladenosine robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines.

HY-N6690

Destruxin B 1 Publications Verification	Infection Microorganisms Classification of Application Fields Cyclopeptides Disease Research Fields Source Classification	Bcl-2 Family Caspase Apoptosis
Destruxin B, isolated from entomopathogenic fungus Metarhizium anisopliae, is one of the cyclodepsipeptides with insecticidal and anticancer activities. Destruxin B induces apoptosis via a Bcl-2 Family-dependent mitochondrial pathway in human nonsmall cell lung cancer cells . Destruxin B significantly activates caspase-3 and reduces tumor cell proliferation through caspase-mediated apoptosis, not only in vitro but also in vivo .

HY-N16403

Aspergillusidone F	Structural Classification Natural Products Microorganisms Source Classification	Cytochrome P450 Endogenous Metabolite Bacterial Insecticide Fungal
Aspergillusidone F is a Depsidone and antibacterial agent. Aspergillusidone F can be isolated from a marine fungus Aspergillus unguis. Aspergillusidone F potently inhibits Aromatase with an IC₅₀ of 0.5 μM. Aspergillusidone F exhibits antibacterial activity against Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. Aspergillusidone F exhibits potent larvicidal activity against Artemia salina larvae, with an LC₅₀ value of 12.8 μM. Aspergillusidone F exhibits anticancer activity against intrahepatic cholangiocarcinoma, non-small cell lung cancer, and acute lymphoblastic leukemia .

HY-N16565

Piperchabamide B	Piper longum Linn. Structural Classification Ketones, Aldehydes, Acids Piperaceae Plants Source Classification	Others
Piperchabamide B is an amide alkaloid. Piperchabamide B can be isolated from the fruits of Piper longum. Piperchabamide B exhibits anticancer activity against acute promyelocytic leukemia, non-small cell lung cancer, and breast cancer .

HY-N2199

Sotetsuflavone	Structural Classification Flavonoids Classification of Application Fields Phenols Polyphenols Selaginellaceae Plants Biflavones Selaginella tamariscina (P. Beauv.) Spring Disease Research Fields Source Classification Cancer	Apoptosis Autophagy PI3K JNK mTOR p38 MAPK CDK MMP TGF-beta/Smad STAT β-catenin Reactive Oxygen Species (ROS) Bcl-2 Family Caspase
Sotetsuflavone is a flavonoid that can be isolated from Cycas revolute. Sotetsuflavone inhibits phosphorylation of PI3K, Akt, mTOR, JNK, and p38 MAPK; modulates expression of Cyclin D1, CDK4, Bcl-2, Bax, cleaved caspases 3/9, MMP-9, TGF-β, STAT3, and β-catenin. Sotetsuflavone induces G₀/G₁ cell cycle arrest, apoptosis, autophagy, and intracellular ROS elevation, inhibits cancer cell proliferation. Sotetsuflavone inhibits tumor growth in mouse tumor xenograft models. Sotetsuflavone can be used for the research of non-small cell lung cancer and Crohn’s disease .

HY-N11912

Soladulcoside A	Solanum nigrum Linn. Plants Solanaceae Steroids Source Classification	Biochemical Assay Reagents
Soladulcoside A is a steroidal glycoside and antineoplastic agent that can be obtained from the whole plant of Solanum nigrum. Soladulcoside A can inhibit A549 cells and has the potential to study cancers such as non-small cell lung cancer (NSCLC) .

HY-N13164

Polygalacin D3	Triterpenes Terpenoids Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Source Classification	PI3K Akt Apoptosis
Polygalacin D3 is a triterpenoid saponin compound that can be extracted from the roots of the balloon flower. Polygalacin D3 can inhibit the proliferation of non-small cell lung cancer (NSCLC) cell lines by blocking the PI3K/Akt pathway, and it induces cell cycle arrest and cell apoptosis .

HY-N15614

Cassamine	Alkaloids Erythrophleum fordii Oliv. Leguminosae Other Alkaloids Plants Source Classification	Others
Cassamine is a diterpenoid compound that can be isolated from the bark of Erythrophleum fordii. Cassamine exhibits certain cytotoxicity against non-small cell lung cancer cell lines, with IC₅₀ values of 3.4, 2.1, and 1.9 μM against A549, NCI-H1975, and NCI-H1299, respectively. Cassamine has antitumor activity and can be used in the research of lung cancer and other tumors .

HY-N3764

Diosbulbin C	Terpenoids Diterpenoids Plants Dioscorea bulbifera Linn. Dioscoreaceae Source Classification	Akt Dihydrofolate reductase (DHFR) Endogenous Metabolite
Diosbulbin C is a diterpene lactone component, which can be extracted from traditional Chinese medicine Dioscorea bulbifera L.. Diosbulbin C possesses high anticancer activity in non-small cell lung cancer (NSCLC). Diosbulbin C could induce cell cycle arrest at G0/G1 phase in NSCLC. Diosbulbin C also inhibits the proliferation of NSCLC cells, possibly by downregulating the expression/activation of AKT, DHFR, and TYMS .

HY-N0816R

Polyphyllin VI (Standard)	Structural Classification other families Plants Steroids Source Classification	Reference Standards Apoptosis Pyroptosis
Polyphyllin VI (Standard) is the analytical standard of Polyphyllin VI. This product is intended for research and analytical applications. Polyphyllin VI, an active saponin, possess anti-cancer activities. Polyphyllin VI induces G2/M cell cycle arrest and triggers apoptosis. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer .

HY-N3126R

Orsellinic acid (Standard)	Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards Drug Derivative Fungal Apoptosis Caspase PARP
Orsellinic acid (Standard) is an analytical standard of Orsellinic acid (HY-N3126). This product is intended for research and analytical applications. Orsellinic acid is a Benzoic acid (HY-N0216) derivative. Orsellinic acid can be isolated from Chaetomium globosum endophytic on Ephedra fasciculata (Mormon tea). Orsellinic acid blocks PAF-mediated Apoptosis, inhibits caspase-3/7 activation, and PARP cleavage. Orsellinic acid can be used in research of neurons and various tumors (non-small cell lung cancer, breast cancer, neuroblastoma, pancreatic cancer) .

HY-128393R

Trilinolein (Standard)	Structural Classification Natural Products Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Plants Endogenous metabolite Araliaceae Source Classification	Reference Standards PI3K Akt E-Selectin Apoptosis MMP MEK ERK
Trilinolein (Standard) is the analytical standard of Trilinolein (HY-128393). This product is intended for research and analytical applications. Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

HY-N0164R

Matrine (Standard) Matridin-15-one (Standard); Vegard (Standard); α-Matrine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Leguminosae Sophora flavescens Aiton Plants Source Classification	PINK1/Parkin Reference Standards Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
Matrine (Standard) is the analytical standard of Matrine. This product is intended for research and analytical applications. Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-N1462R

Atractyloside potassium salt (Standard)	Structural Classification Terpenoids Pterocarpus soyauxii Taub. Diterpenoids Plants Compositae Source Classification	Reference Standards Chloride Channel Autophagy mTOR AMPK
Atractyloside (potassium salt) (Standard) is the analytical standard of Atractyloside (potassium salt). This product is intended for use in research and analytical applications. Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity .

HY-N1988R

Cucurbitacin IIa (Standard) Hemslecin A (Standard)	Triterpenes Structural Classification Terpenoids Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Source Classification	Reference Standards Apoptosis EGFR Autophagy MEK Caspase ERK STAT Survivin Raf p38 MAPK CaMK
Cucurbitacin IIa (Hemslecin A) (Standard) is the analytical standard for Cucurbitacin IIa (HY-N1988). This product is used for research and analytical applications. Cucurbitacin IIa is an orally active, blood-brain barrier-penetrating EGFR inhibitor with an IC₅₀ of 1.455 nM for human EGFR. Cucurbitacin IIa induces caspase-3 dependent cell apoptosis, downregulates survivin expression, enhances autophagy levels, disrupts the actin cytoskeleton through actin aggregation, blocks the cell cycle at the G2/M phase, and inhibits the EGFR-MAPK signaling pathway to exert anti-inflammatory activity. Cucurbitacin IIa can be used in research on inflammatory-related diseases, depression, and non-small cell lung cancer and other cancers.

HY-N17684

Abietatriene-3β-ol	Structural Classification Natural Products Platycladus orientalis (Linn.) Franco Cupressaceae Plants Source Classification	Others
Abietatriene-3β-ol is an anticancer agent. Abietatriene-3β-ol can be isolated from leaves of Thuja orientalis L. Abietatriene-3β-ol exhibits anticancer activity against non-small cell lung adenocarcinoma, ovarian cancer cells, skin melanoma, and colon cancer .

HY-N4309A

Lotusine hydroxide	Cardiovascular Disease Alkaloids Classification of Application Fields Phenols Polyphenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Nymphaeaceae Disease Research Fields Source Classification	Amylases Glycosidase
Lotusine hydroxide is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against α-amylase and an IC₅₀ of 36.15 μg/mL against α-glucosidase. Lotusine hydroxide inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine hydroxide induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine hydroxide reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine hydroxide is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-N2993R

Polyporenic acid C (Standard)	Triterpenes Structural Classification Terpenoids Polyporaceae Poria cocos Plants Source Classification	Reference Standards Apoptosis Caspase PARP Akt PTEN MDM-2/p53 JNK
Polyporenic acid C (Standard) is an analytical standard of Polyporenic acid C (HY-N2993). This product is intended for research and analytical applications. Polyporenic acid C is a lanostane-type triterpenoid. Polyporenic acid C can be isolated from Poria cocos. Polyporenic acid C causes the cleavage of caspase-8 and caspase-3, as well as the cleavage of PARP. Polyporenic acid C reduces the phosphorylation level of Akt (Ser473), increases the phosphorylation of PTEN and p53 (Ser15), and activates JNK. Polyporenic acid C induces Apoptosis. Polyporenic acid C shows anticancer activity against non-small cell lung cancer .

Cat. No.	Product Name	Chemical Structure

HY-19939S

VX-984 4 Publications Verification
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-114277S

Sotorasib-d7

Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC) .

HY-142283AS

Dosimertinib-d5 mesylate
Dosimertinib-d₅ (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d₅ (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₅ (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d₅ (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC) .

HY-142283

Dosimertinib
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC) .

HY-W654256

Matrine-d3

Matrine-d₃ (Matridin-d₃) is a deuterium labeled Matrine (HY-N0164). Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-114277S2

Sotorasib-d3
Sotorasib-d₃ (AMG-510-d₃) is deuterium labeled Sotorasib. Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC) .

HY-168968S

ZJY-54
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC₅₀ values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity .

HY-128393S1

Trilinolein-13C54

Trilinolein- ¹³C₅₄ is the ¹³C-labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

HY-50896S3

Erlotinib-d8

Erlotinib-d₈ (CP-358774-d₈) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50896S2

Erlotinib-d4

Erlotinib-d₄ (CP-358774-d₄) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W750535

Triglycidyl Isocyanurate-d15

Triglycidyl Isocyanurate-d₁₅ is the deuterium labeled Triglycidyl isocyanurate (HY-W011434). Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research .

HY-121246S

Fluorofenidone-d3

Fluorofenidone-d₃ (AKF-PD-d3) is deuterium labeled Fluorofenidone (AKF-PD) (HY-121246). Fluorofenidone is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .

HY-172733S

PRMT5-MTA-IN-3-d3

PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

HY-W009538S

5'-Deoxy-5-fluorocytidine-d3

5'-Deoxy-5-fluorocytidine-d₃ is deuterated labeled 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

HY-W009538S1

5'-Deoxy-5-fluorocytidine-13C5

5'-Deoxy-5-fluorocytidine-13C5 is the ¹³C labeled isotope of 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer .

HY-W018324S

5-Hydroxymethylcytosine-13C,d2

5-Hydroxymethylcytosine- ¹³C,d₂ is the ¹³C and deuterium labeled 5-Hydroxymethylcytosine (HY-W018324). 5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) .

HY-112870AS

Firmonertinib-d3 mesylate

Firmonertinib-d₃ (Alflutinib-d₃) mesylate is the deuterium labeled Firmonertinib mesylate (HY-112870A). Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.

HY-128393S2

Trilinolein-d5

Trilinolein-d₅ is the deuterium labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

HY-112823S

Almonertinib-d6

Almonertinib-d₆ (HS-10296-d₆) is the deuterium labeled Almonertinib (HY-112823). Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer .

Targets Recommended: BCRP Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15947G

Ravoxertinib GDC-0994	ERK c-Myc Hexokinase Lactate Dehydrogenase	Cancer
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .

HY-12299G

WH-4-023 Dual LCK/SRC inhibitor	Src	Cancer
WH-4-023 GMP is WH-4-023 (HY-12299) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. WH-4-023 (Dual LCK/SRC inhibitor) is a Lck/Src dual target inhibitor with functions in stem cell maintenance and differentiation regulation. WH-4-023 blocks epithelial-mesenchymal transition, supports the self-renewal of porcine embryonic stem cells, and inhibits their differentiation into mesoderm and endoderm. WH-4-023 is a key component of 3i/LAF medium, and enables the stable establishment and long-term maintenance of porcine pre-gastrulation epiblast stem cell lines. Removal of WH-4-023 reduces the expression of pluripotency factors in porcine and human extended pluripotent stem cells. WH-4-023 can be applied to relevant studies such as non-small cell lung cancer resistant to EGFR-TKIs .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks